2016
DOI: 10.1016/j.addr.2015.06.001
|View full text |Cite
|
Sign up to set email alerts
|

Vascularization strategies of engineered tissues and their application in cardiac regeneration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
88
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 121 publications
(95 citation statements)
references
References 129 publications
1
88
0
Order By: Relevance
“…Freshly isolated SVF cells were reported to possess a superior capacity to generate in vitro microvessels compared to other prevascularization approaches based on the coculture of endothelial cells and either mesenchymal stem cells or perivascular cells [6].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Freshly isolated SVF cells were reported to possess a superior capacity to generate in vitro microvessels compared to other prevascularization approaches based on the coculture of endothelial cells and either mesenchymal stem cells or perivascular cells [6].…”
Section: Discussionmentioning
confidence: 99%
“…myocardium) [5], whereas other tissues retain their function upon implantation only if their avascular nature is preserved in healthy condition (e.g. hyaline cartilage, cardiac valve substitute) [6][7][8]. Biomaterials alone could block or promote angiogenesis via functionalization, architecture, or composition [9].…”
Section: Introductionmentioning
confidence: 99%
“…Embryonic stem cells (ESCs) are pluripotent stem cells derived from the blastocyst stage of early mammalian embryogenesis, and are able to differentiate into any cell type [93]. As such, ESCs can differentiate and propagate, devoid of reprogramming induced genomic alterations and mutations [94].…”
Section: D Bioprinting Of the Cardiovascular Systemmentioning
confidence: 99%
“…In cardiovascular regeneration, vascularization is arguably the most important issue. The primary sources of ECs utilized experimentally are from the aorta and human umbilical vein, however, autologous cell sources such as iPSC-derived ECs or blood/bone marrow-derived endothelial progenitor cells, are more likely to be applied clinically due to their non-immunogenicity [87,93]. The source and phenotype of the ECs may also play an important role in their function, as ECs differ in functionality between different organs, but also within different parts of the heart [12,93].…”
Section: D Bioprinting Of the Cardiovascular Systemmentioning
confidence: 99%
See 1 more Smart Citation